"Patent-Protected Herbal Anticancer Compounds | OEMSolutions for Pharma & Nutraceutical Companies"

Article Title:

"Patent-Protected Herbal Anticancer Compounds | OEMSolutions for Pharma & Nutraceutical Companies"

Meta Description:

Blue Eyes Biotech offers patent-protected tumor-fightingherbal compounds & end-to-end OEM services for pharma companies. CustomizedGMP extracts with clinical validation. Contact

[email protected]

forformulations.

Innovative Plant-Derived OncologySolutions: Proprietary Compounds & Tailored OEM Services

Blue Eyes Biotech Co., Ltd bridgestraditional herbal wisdom with modern pharmaceutical rigor, deliveringpatent-protected anticancer botanicals and white-label manufacturing servicesfor global drug developers. Our portfolio targets eight key mechanisms of tumorsuppression, validated by 38 clinical studies and protected by 12 internationalpatents.

Core Technology Differentiators

1. Exclusive Patent Portfolio

   ·Withaferin A SynComplex®: Novel Ashwagandha-based formulation (Patent No.US2024034742A1) with 3x higher bioavailability than standard extracts,specifically inhibiting PRMT proteins implicated in breast/colon cancers.

   ·Euphorbia-Derived Cytotoxins: Licensed Euphorbia peplus sap compounds (US6787161B2)for topical SCC/melanoma therapies, achieving 92% selective necrosis in phaseII trials.

2. Multi-Target Action

  Our compounds address critical pathways:

   ·Apoptosis induction: Curcumin C3 Complex® with 70% caspase-3 activation

   ·Immune checkpoint modulation: Beta-glucan 85% for PD-1/CTLA-4 synergy

   ·MDR reversal: Berberine-quercetin nanoemulsions (Patent pending)

3. Pharma-Grade OEM Capabilities

   · Custom Extraction: From 10:1concentrates to USP-grade APIs (e.g., ≥98% paclitaxel alternatives)

   ·Formulation Development: Liposomal/nanoparticle systems for enhanced tumorpenetration

   ·Regulatory Support: Complete DMF/ASMF dossiers for FDA/EMA submissions

Why Partner With Us?

· IPProtection Guarantee: All formulations include territory-specific patentlicensing to prevent generics competition.

· ClinicalBacking: 80% of compounds have published data in Nature Communications orJournal of Biological Chemistry.

· ScalableProduction: Blockchain-tracked supply chain from organic farms to GMPfacilities (200-ton annual capacity).

Request a Technology Dossier:

For formulation prototypes, patentlandscapes, or co-development opportunities, contact [email protected] orvisit www.blueeyes-bio.com